The Motley Fool··Seena HassounaSpecialist Biotech Fund's $25.8M Spyre Bet Signals Confidence in Preclinical Pipeline
VR Adviser increased Spyre Therapeutics stake by 1M shares to $120.74M. Stock surged 132% annually, but preclinical risks remain high for retail investors.
SYREbiotech investmentmonoclonal antibodies